

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

BA

PATENT SPECIFICATION

(11) 1269 291

NO DRAWINGS


- (21) Application No. 16444/70 (22) Filed 7 April 1970
 (31) Convention Application No. 817564 (32) Filed 18 April 1969 in
 (33) United States of America (US)
 (45) Complete Specification published 6 April 1972
 (51) International Classification C 07 c 173/00
 (52) Index at acceptance
 C2U 2 3 4A2 4B2 4C4 4C5 4D 4X



(54) IMPROVEMENTS IN OR RELATING TO CORTICOID CARBONATES

(71) We, SYNTEX CORPORATION, a Panamanian Corporation of Apartado Postal 7386, Panama, Panama, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to novel cyclopentanophenanthrene derivatives. More particularly, this invention is directed to 21-corticoid carbonates which can be represented by the following general formula:



wherein,

- R¹ is fluoro or chloro;
 R² is hydrogen, fluoro or chloro;
 R³ is hydroxy or when R² is chloro, R³ can be chloro;
 R⁴ is lower alkyl, cycloalkyl, or aralkyl;
 P and Q are hydrogen, lower alkyl, halogenated lower alkyl monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic, or monocyclic heterocyclic lower alkyl, or together with the carbon atoms to which they are joined P and Q are cycloalkyl or monocyclic heterocyclic; and
 Z¹ is a single or double bond.

The above novel compounds of this invention have anti-inflammatory, glycogenic, thymolytic, anti-estrogenic and anti-androgenic activity and can be used in the same manner for the same purposes as 6 α ,9 α -difluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione 16 α ,17 α -acetonide (fluocinolone acetonide). They are particularly useful for topical treatment of skin inflammation and similar skin disorders, and for this purpose can be used together with the conventional excipients in the conventional bases used for topical preparation. The invention includes therapeutic compositions comprising compounds of formula I in suitable pharmaceutical excipients.


The term "lower alkyl" and derivations thereof appearing in the above definitions and elsewhere in the instant specification denote alkyl groups containing 1 to 6 carbon atoms, inclusive, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, amyl, hexyl, and the like. The term "cycloalkyl" denotes cycloalkyl groups having from 3 to 10 carbons such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, 3-(cyclohexyl)-

[Price 25p]


SEE ERRATA SLIP ATTACHED

propyl, and the like. The term "aralkyl" and derivations thereof appearing in the above definitions and elsewhere in the instant specification denote phenylalkyl and substituted phenylalkyl groups containing from 7 to 10 carbon atoms, inclusive, such as benzyl, *o*-, *m*- and *p*-methylbenzyl, phenylethyl and 3-(phenyl)propyl.

The compounds of Formula I are prepared according to this invention by reacting a steroid of the general formula



wherein R^1 , R^2 , R^3 , P , Q and Z^1 are as previously defined with a chloroformate having the general formula:



wherein R^4 is as previously defined. The steroid of Formula A can be reacted in a pyridine solution with the chlorocarbonate of Formula B in excess of one mole of the steroid. The reaction can be conducted in the presence of a cosolvent such as chloroform, dichloromethane, monoglyme, or tetrahydrofuran since the neat pyridine solution may cause some decomposition of certain of the reactants. The reaction is conducted at a temperature of from -70° to 20°C , for from 5 to 48 hours, preferably for 18 hours at 0°C , and purified by conventional procedures. For example, the reaction mixture containing the product carbonate can be diluted with water, filtered, and the solid product dried and purified by crystallization or chromatography on silica gel to yield the 21-corticoid carbonates of Formula I.

The chloroformates of Formula B together with representative procedures for reacting them with steroids are disclosed in U.S. Patents 3,056,727, 3,314,856, 3,329,570, 3,409,641 and Belgium Patent 706,333. In general, the chloroformates are formed by reacting a corresponding alcohol with an excess of phosgene in a suitable inert organic solvent to obtain the chlorocarbonate. For example, phosgene can be allowed to bubble for a period of 1.5 hours into 120 cc. of anhydrous ethanol cooled to 0°C . Then 30 g. of cyclohexylmethanol is introduced. The reaction mixture is then agitated at 0°C for a period of 24 hours, the phosgene is removed by bubbling nitrogen therethrough, and the mixture is concentrated to dryness under vacuum to yield the cyclohexylmethyl chloroformate.

Other suitable chloroformates include methyl chloroformate, ethyl chloroformate, *n*-propyl chloroformate, cyclohexyl chloroformate and benzyl chloroformate.

The compounds of Formula A are described together with methods for their preparation in U.S. Patent 3,053,838. Among the suitable starting steroids useful in the process of this invention can be mentioned the $16\alpha,17\alpha$ -acetal derivatives of

6α -fluoro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregn-4-ene-3,20-dione,
 6α -chloro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregn-4-ene-3,20-dione,
 $6\alpha,9\alpha$ -difluoro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregn-4-ene-3,20-dione,
 $6\alpha,9\alpha$ -dichloro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregn-4-ene-3,20-dione,
 6α -chloro- 9α -fluoro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregn-4-ene-3,20-dione,
 9α -chloro- 6α -fluoro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregn-4-ene-3,20-dione,
 $6\alpha,9\alpha,11\beta$ -trichloro- $16\alpha,17\alpha,21$ -trihydroxypregn-4-ene-3,20-dione,
 $9\alpha,11\beta$ -dichloro- 6α -fluoro- $16\alpha,17\alpha,21$ -trihydroxypregn-4-ene-3,20-dione,
 6α -fluoro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregna-1,4-diene-3,20-dione,
 6α -fluoro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregna-1,4-diene-3,20-dione,
 $6\alpha,9\alpha$ -difluoro- $11\beta,16\alpha,17\alpha,21$ -tetrahydroxypregna-1,4-diene-3,20-dione,

5 6 α ,9 α -dichloro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione,
6 α -chloro-9 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione,
9 α -chloro-6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione,
6 α ,9 α ,11 β -trichloro-16 α ,17 α ,21-trihydroxypregna-1,4-diene-3,20-dione, and
9 α ,11 β -dichloro-6 α -fluoro 16 α ,17 α ,21-trihydroxypregna-1,4-diene-3,20-dione,
with lower alkanals such as paraldehyde, propanal, and hexanal; halogenated lower
alkanals such as chloral hydrate trifluoroacetaldehyde hemiacetal and hepta fluoro-
butanal ethyl hemiacetal; di(lower alkyl)ketones, such as acetone, diethylketone, di-
10 butylketone, methylethylketone, and methylisobutylketone; halogenated di(lower alkyl)-
ketones, such as 1,1,1-trifluoroacetone; cycloalkanones, such as cyclopentanone, cyclo-
hexanone, suberone, cyclobutanone, and cyclodecanone; mono- and dicycloalkyl
ketones, such as cyclohexylmethyl ketone and dicyclopropyl ketone; monocyclic
aromatic aldehydes, such as benzaldehyde, halobenzaldehydes (e.g. *p*-chlorobenzalde-
15 hyde and *p*-fluorobenzaldehyde), lower alkoxy benzaldehydes (e.g. *o*-anisaldehyde),
di(lower alkoxy)benzaldehydes (e.g. veratraldehyde), hydroxybenzaldehydes (e.g. sali-
cylaldehyde), dihydroxybenzaldehydes (e.g. resorcydaldehyde), lower alkyl benzalde-
hydes (e.g. *m*-tolualdehyde and *p*-ethylbenzaldehyde), di(lower alkyl)benzaldehydes
(e.g. *o,p*-dimethylbenzaldehyde), nitrobenzaldehydes, acylamidobenzaldehydes (e.g. N-
20 acetylantbranildaldehyde), and cyanobenzaldehydes; monocyclic aromatic lower
alkanals, such as phenylacetaldehyde, α -phenylpropionaldehyde, β -phenylpropionalde-
hyde, γ -phenylbutyraldehyde, and aromatically-substituted halo, lower alkoxy, hydroxy,
lower alkyl, nitro, acylamido and cyano derivatives thereof; monocyclic heterocyclic
aldehydes, such as picolinaldehydes, furfural, thiophene carbonals and halo, lower
25 alkoxy, hydroxy, lower alkyl, nitro, and cyano derivatives thereof; monocyclic hetero-
cyclic lower alkanals; monocyclic aromatic lower alkyl ketones, such as acetophenone,
propiophenone, butyrophenone, valerophenone, iso-caprophenone, halophenyl lower
alkyl ketones (e.g. *p*-chloroacetophenone and *p*-chloropropiophenone), (lower alkoxy)-
phenyl lower alkyl ketones (e.g. *p*-anisyl methyl ketone), di(lower alkoxy)phenyl lower
30 alkyl ketones, hydroxyphenyl lower alkyl ketones, dihydroxyphenyl lower alkyl ketones
(e.g. resacetophenone), (lower alkyl)phenyl lower alkyl ketones (e.g. methyl *p*-tolyl
ketone, di(lower alkyl)phenyl lower alkyl ketones (α,p -xylyl methyl ketone), nitro-
phenyl lower alkyl ketones (e.g. *p*-nitroacetophenone), acylamidophenyl lower alkyl
ketones (e.g. acetylanilines), and cyanophenyl lower alkyl ketones; benzophenone, and
35 mono or bis substituted halo, lower alkoxy, hydroxy, lower alkyl, nitro, acylamido
and cyano derivatives thereof; monocyclic aromatic lower alkanones, such as 1-phenyl-
3-butanone and 1-phenyl-4-pentanone, and aromatically substituted derivatives there-
of; monocyclic heterocyclic ketones, such as 2-acetylthiophene, 2-benzoylthiophene, and 2-
acetylthiophene; monocyclic heterocyclic lower alkanones; and monocyclic hetero-
cyclic ketones, such as alloxan.

40 **EXAMPLE 1**
Ethyl chloroformate (1 ml.) is added to a solution of 6 α ,9 α -difluoro-11 β ,16 α ,17 α ,
21-tetrahydroxypregna-1,4-diene-3,20-dione 16 α ,17 α -acetone (500 mg.) in pyridine
(15 ml.) at 0°C. The reaction mixture is maintained at 0°C for 18 hours, poured
45 into water, filtered, washed with water, and crystallized from acetone-hexane to yield
6 α ,9 α -difluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone 21-ethyl-carbonate.

EXAMPLE 2
Repeating the procedure of Example 1 with
50 6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-4-ene-3,20-dione 16 α ,17 α -
acetone,
6 α -chloro-11 β ,16 α ,17 α ,21-tetrahydroxypregn-4-ene-3,20-dione 16 α ,17 α -
acetone,
6 α ,9 α -difluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregn-4-ene-3,20-dione 16 α ,17 α -
55 acetone,
6 α ,9 α -dichloro-11 β ,16 α ,17 α ,21-tetrahydroxypregn-4-ene-3,20-dione 16 α ,17 α -
acetone,
6 α -chloro-9 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregn-4-ene-3,20-dione
16 α ,17 α -acetone,
60 9 α -chloro-6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregn-4-ene-3,20-dione
16 α ,17 α -acetone,
6 α ,9 α ,11 β -trichloro-16 α ,17 α ,21-trihydroxypregn-4-ene-3,20-dione 16 α ,17 α -
acetone,

- 9 α ,11 β -dichloro-6 α -fluoro-16 α ,17 α ,21-trihydroxypregna-4-ene-3,20-dione
16 α ,17 α -acetone,
6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione 16 α ,17 α -
acetone,
5 6 α -chloro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione 16 α ,17 α -
acetone,
6 α -chloro-9 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone,
10 9 α -chloro-6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone,
6 α ,9 α ,11 β -trichloro-16 α ,17 α ,21-trihydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone, and
9 α ,11 β -dichloro-6 α -fluoro-16 α ,17 α ,21-trihydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone,
15 yields the corresponding 21-ethyl carbonates. 15

EXAMPLE 3

- Repeating the procedures of Examples 1 and 2 but replacing ethyl chloroformate
with methyl chloroformate, n-propyl chloroformate, n-pentyl chloroformate, cyclo-
propyl chloroformate, cyclopentyl chloroformate, cyclohexyl chloroformate, cyclo-
propylethyl chloroformate, cyclopentylmethyl chloroformate, cyclohexyl ethyl chloro-
formate, benzyl chloroformate, and p-methylbenzyl chloroformate yields the corres-
ponding 21-methyl carbonate, 21 - (n - propyl)carbonate, 21 - (n - pentyl)carbonate,
21-cyclopropyl carbonate, 21-cyclopentyl carbonate, 21-cyclohexyl carbonate, 21-
cyclopropyl carbonate, 21-cyclopentylmethyl carbonate, 21-cyclohexylethyl carbonate,
21-benzyl carbonate, and 21-(p-methylbenzyl)carbonate of
6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypreg-4-ene-3,20-dione 16 α ,17 α -acetone,
6 α -chloro-11 β ,16 α ,17 α ,21-tetrahydroxypreg-4-ene-3,20-dione 16 α ,17 α -acetone,
6 α ,9 α -difluoro-11 β ,16 α ,17 α ,21-tetrahydroxypreg-4-ene-3,20-dione 16 α ,17 α -
acetone,
30 6 α ,9 α -dichloro-11 β ,16 α ,17 α ,21-tetrahydroxypreg-4-ene-3,20-dione 16 α ,17 α -
acetone,
6 α -chloro-9 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypreg-4-ene-3,20-dione
16 α ,17 α -acetone,
35 9 α -chloro-6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypreg-4-ene-3,20-dione
16 α ,17 α -acetone,
6 α ,9 α ,11 β -trichloro-16 α ,17 α ,21-trihydroxypreg-4-ene-3,20-dione 16 α ,17 α -
acetone,
9 α ,11 β -dichloro-6 α -fluoro-16 α ,17 α ,21-trihydroxypreg-4-ene-3,20-dione
16 α ,17 α -acetone,
40 6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione 16 α ,17 α -
acetone,
6 α -chloro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione 16 α ,17 α -
acetone,
6 α ,9 α -difluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone,
45 6 α -chloro-9 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone,
9 α -chloro-6 α -fluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone,
50 6 α ,9 α ,11 β -trichloro-16 α ,17 α ,21-trihydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone, and
9 α ,11 β -dichloro-6 α -fluoro-16 α ,17 α ,21-trihydroxypregna-1,4-diene-3,20-dione
16 α ,17 α -acetone.

EXAMPLE 4

- Following the procedure of Example 1, 21-ethylcarbonates of 6 α ,9 α - difluoro-
11 β ,16 α ,17 α ,21 - tetrahydroxypregna - 1,4 - diene - 3,20 - dione 16 α ,17 α - acetals,
wherein the 16 α ,17 α -acetal groups are acetals of propanal, hexanal, chloral hydrate,
trifluoroacetaldehyde hemiacetal, hepta fluorobutanal ethyl hemiacetal, acetone, di-
ethylketone, dibutylketone, methylethylketone, methylisobutylketone, 1,1,1-trifluoro-
acetone, cyclopentanone, cyclohexanone, suberone, cyclobutanone, cyclodecanone,
60 cyclohexylmethylketone, dicyclopropylketone, benzaldehyde, p-chlorobenzaldehyde, p-
fluorobenzaldehyde, o-anisaldehyde, veratraldehyde, salicylaldehyde, m-tolualdehyde,
p-ethylbenzaldehyde, o,p-dimethylbenzaldehyde, phenylacetaldehyde, α -phenylpro-

pionaldehyde, β -phenylpropionaldehyde, picolinaldehyde, furfuraldehyde, acetophenone, propiophenone, butyrophenone, valerophenone, isocaprophenone, *p*-chloroacetophenone, *p*-chlororopiophenone, *p*-anisyl methyl ketone, methyl *p*-tolyl ketone, α ,*p*-xylyl methyl ketone, benzophenone, 1-phenyl-3-butanone, 1-phenyl-4-pentanone, 2-acetylfuran, 2-benzoylfuran, 2-acetylthiophene, and alloxan are obtained from the corresponding 21-hydroxy compounds.

EXAMPLE 5

Improved anti-inflammatory activity of the compounds of this invention is demonstrated as follows. A "rat-ear" test was used to compare the anti-inflammatory activity of 6 α ,9 α -difluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione-16 α ,17 α -acetone (Compound A) with 6 α ,9 α -difluoro-11 β ,16 α ,17 α ,21-tetrahydroxypregna-1,4-diene-3,20-dione 16 α ,17 α -acetone (Compound B) the latter compound being a commercial anti-inflammatory compound having the generic name fluocinolone acetone.

The test is a modification of a method originally described by Tonelli, et al in Endocrinology 77, 625 (1965). A vehicle consisting of 20% pyridine, 5% distilled water, 74% diethyl ether and 1% croton oil is used. Intact male 21-day-old rats are anesthetized, and the test compound is injected onto the ear as follows: 0.05 ml. is injected onto the inside of the left ear and 0.05 ml. is injected onto the outside of the left ear. The vehicle containing the irritant is given simultaneously with the anti-inflammatory compound. Rats in a control group receive only the vehicle. Both ears are removed 6 hours after administration of the compound, and pieces of uniform size are punched out with a No. 4 cork borer. The pieces of ear are then weighed and the difference in weight increase between the two pieces of ear are determined.

The data obtained is summarized in Table 1 showing the activity in comparison with the activity of hydrocortisone.


| Table 1 | | | |
|----------|-------------|-----------------------------|-------------------------|
| Compound | No. of rats | Dose range tested, μ g. | Activity ^(a) |
| A | 84 | 0.1—2.7 | 390 |
| B | 235 | 0.05—2.7 | 150 |

^(a) hydrocortisone has an activity value of one.

As can be readily seen from the data in Table 1, as measured by the rat-ear test, the 21-ethylcarbonate is 2.6 times as active as the corresponding 21-hydroxy compound.

WHAT WE CLAIM IS:—

1. A compound of the formula:



wherein

R¹ is fluoro or chloro;


R² is hydrogen, fluoro or chloro;

R³ is hydroxy or when R³ is chloro, R³ can be chloro;

R⁴ is lower alkyl, cycloalkyl or aralkyl;


P and Q are hydrogen, lower alkyl, halogenated lower alkyl, monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic or monocyclic heterocyclic lower alkyl or together with the carbon atoms to which they are joined P and Q are cycloalkyl or monocyclic heterocyclic and

- Z^1 is a single or double bond.
2. A compound of Claim 1 wherein R^4 is methyl, ethyl, n-propyl, cyclohexyl, or cyclohexylmethyl.
3. A compound of Claim 1 wherein R^4 is lower alkyl.
- 5 4. A compound of Claim 3 wherein P and Q, together with the carbon atom to which they are joined are cyclopentyl or cyclohexyl.
5. A compound of Claim 4 wherein R^3 is hydrogen.
6. A compound of Claim 4 wherein R^3 is fluoro.
7. A compound of Claim 3 wherein P and Q are methyl.
- 10 8. A compound of Claim 7 wherein R^3 is hydrogen.
9. As a compound of Claim 8, 6 α - fluoro - 11 β ,21 - dihydroxy - 16 α ,17 α - isopropylidenedioxypregn - 4 - ene - 3,20 - dione 21-ethyl-carbonate.
10. As a compound of Claim 8, 6 α - fluoro - 11 β ,21 - dihydroxy - 16 α ,17 α - isopropylidenedioxypregna - 1,4 - diene - 3,20 - dione 21-ethylcarbonate.
- 15 11. A compound of Claim 7 wherein R^3 is fluoro.
12. As a compound of Claim 11, 6 α ,9 α - difluoro - 11 β ,21 - dihydroxy - 16 α ,17 α - isopropylidenedioxypregn - 4 - ene - 3,20 - dione 21-ethylcarbonate.
13. As a compound of Claim 11, 9 α ,11 β - dichloro - 6 α - fluoro - 21 - hydroxy - 16 α ,17 α - isopropylidenedioxypregna - 1,4 - diene - 3,20 - dione 21-ethylcarbonate.
- 20 14. The process for the preparation of a 21-carbonate ester of the general formula:



wherein

- 25 R^1 is fluoro or chloro;
- R^2 is hydrogen, fluoro or chloro;
- R^3 is hydroxy or when R^2 is chloro, R^3 can be chloro;
- R^4 is lower alkyl, cycloalkyl or aralkyl;
- P and Q are hydrogen, lower alkyl, halogenated lower alkyl, monocyclic cycloalkyl, monocyclic aryl, monocyclic aryl lower alkyl, monocyclic heterocyclic or monocyclic heterocyclic lower alkyl or together with the carbon atom to which they are joined P and Q are cycloalkyl or monocyclic heterocyclic, and Z^1 is a single or double bond;
- 30 which comprises reacting together a corresponding 21-hydroxy starting steroid, and a chloroformate of the formula:



wherein R^4 is lower alkyl, cycloalkyl, or aralkyl.

15. A compound according to Claim 1 substantially as herein described and exemplified.

16. Process according to Claim 1 substantially as herein described and exemplified.

17. A 21-carbonate ester having the general formula as defined in Claim 14 when obtained by the process claimed in Claim 14 or Claim 16.

18. A therapeutic composition comprising a compound as claimed in any one of Claims 1 to 13 or Claim 15, or Claim 17 and a pharmaceutical excipient.
19. Therapeutic composition according to Claim 18 substantially as herein described.

MEWBURN ELLIS & CO.,
Chartered Patent Agents,
70-72 Chancery Lane,
London W.C.2.
Agents for the Applicants.

Printed for Her Majesty's Stationery Office, by the Courier Press, Leamington Spa, 1972.
Published by The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from
which copies may be obtained.